Tanvex BioPharma, Inc. 英屬開曼群島商泰福生技股份有限公司 (the "Company")

2025年股東常會開會通知書 2025 Annual General Meeting Notice

一、茲訂於台灣時間西元2025年6月5日上午9時整假台北市中正區中山南路11號10樓(張榮發基金會國際會議中心)【受理股東報 到時間:上午8:30起,報到處地點同開會地點】舉行本公司2025年股東常會,會議召集事由:(一)報告事項:1.2024年度營 業報告。2.2024年度審計委員會審查報告。3.審計委員會與內部稽核主管之溝通情形報告。4.2024年健全營運計劃執行情形 報告。(二)承認事項:1.2024年度營業報告書及合併財務報告案。2.2024年度虧損撥補案。(三)討論事項:修訂「公司章程」 部分條文案(本案應以特別決議通過)。(四)臨時動議。

Please be informed that the Company's 2025 Annual General Meeting (The "Meeting") is scheduled to be convened at CHANG YUNG-FA FOUNDATION International Convention Center, 10F, No. 11, Zhongshan S. Rd., Zhongzheng Dist., Taipei City, Taiwan (R.O.C.), at 9:00 a.m., June 5, 2025. (The registration time is from 8:30 a.m. at the same venue as the Meeting)

The Agenda of the Meeting:

- 1.Reporting Items:
- (1)2024 Business Report.
- (2) Audit Committee's Review Report on 2024 Financial Statements
- (3) Audit Committee and Internal Auditor Communication and Discussion Report.
- (4) For the 2024 Financial Report and the Execution Status of Sound Business Plan.
- 2.Recognition Items
- (1)2024 Business Report and Consolidated Financial Report
- (2)2024 Deficit Compensation.
- 3. Discussion Items:

Proposal for Amendments to Certain Articles of the Company's "Articles of Association". (To be approved by special

- 二、依中華民國公開發行公司相關規定應說明其主要內容置於公開資訊觀測站,查詢網址爲: 【https://mops.twse.com.tw】。 Pursuant to the applicable public company rules of R.O.C., the Main Points of certain Discussion Items shall be uploaded to Market Observation Post System ("MOPS"), available at https://mops.twse.com.tw
- 三、貴股東欲親自出席股東會時,請於「出席簽到卡」上簽名或蓋章後,於開會當日攜往會場辦理報到並繳交以出席股東會, 如 委託代理人出席時, 請於「委託書」 上簽名或蓋章, 並親填受託代理人姓名及地址後, 於開會五日前送達本公司股務代理 人中國信託商業銀行代理部,以憑寄發出席簽到卡予受託代理人。

Please sign or seal in the "Attendance Card" while you want to attend the meeting in person. Shareholder may sign or seal in the "Proxy Statement" to appoint a proxy in writing to attend the meeting on his or her behalf by executing a power of attorney. Please send out such written "Proxy Statement" to the Company's Stock Affairs Agency, Stock Affairs Agency Department of CTBC Bank Co., Ltd., no later than five days prior to the meeting date for processing the "Attendance Card" to the proxy recipient.

四、如有股東徽求委託書,本公司將於西元2025年5月5日製作徽求人徽求資料彙總表冊揭露於證基會網站,投資人如欲查詢,可 直接鍵入(https://free.sfi.org.tw)至「委託書公告資料免費查詢」系統,輸入查詢條件即可。

The Company will compile a summary statement of the relevant information solicited by shareholders through solicitation for the proxy and disclose the content in the website of Securities & Futures Institute (SFI) on May 5, 2025. Investors can link with SFI's web address (https://free.sfi.org.tw) of relevant information

五、本次股東會得以電子方式行使表決權,行使期間為:自西元2025年5月6日起至2025年6月2日止,請逕登入臺灣集中保管結算 所股份有限公司「股東會電子投票平台」【https://stockservices.tdcc.com.tw】,依相關說明操作之。

The meeting will adopt electronic voting as one of the methods for members to vote for resolutions. For voting on line, the electronic voting platform of Taiwan Depositary and Clearing Corporation will be available at https:// stockservices.tdcc.com.tw beginning from May 6, 2025 to June 2, 2025. Please log in and vote in accordance with the instructions

六、新開户股東如擬繳交股東印鑑卡,可至本公司股務代理人中信銀法人信託網站下載印鑑卡使用。

Newly opened account shareholders who intend to submit their shareholder seal card can download the seal card for use from CTBCTRUST BANKING ONLINE BANKING offered by our stock affairs agency, CTBC Bank Co., Ltd.

本次股東會委託書之統計驗證機構爲中國信託商業銀行代理部。

The proxies shall be tallied and verified by the Stock Affairs Agency Department of CTBC Bank Co., Ltd.

八、敬請察照辦理為荷

Please execute as above-mentioned.

此致 貴股東

英屬開曼群島商泰福生技股份有限公司 董事會 Board of Directors of Tanvex BioPharma, Inc.

中信銀爲境內外處理股務業務之目的,在法令規定、相關事實或法律關係存續之 期間,就直接或間接(例如透過集保)蒐集與股務相關之您的個人資料,將以書面 及/或電子等形式處理、利用及/或國際傳輸,例如揭露予公務機關或協助處理股 務之第三人。您得要求查詢、閱覽、製給複本、補充或更正、停止蒐集、處理、 利用及/或國際傳輸或刪除您的個人資料,但中信銀可能因此無法提供您所需服務, 亦可能依法或基於風險管理等因素而得不依您的請求爲之。

In order for CTBC Bank Co., Ltd. (CTBC) to handle the stock matters domestically and internationally during the service period stipulated by laws and regulations or the duration of related facts or legal relationship, CTBC will process, use and/or internationally transmit, in the form of writing and/or electronic files and others, such as disclosure to government agencies or a third party assisting the stock matters, your personal information regarding stock matters which has been directly or indirectly collected by CTBC (for example, from TDCC). You may request for inquiry, review, duplicates, supplement, correction and deletion of your personal information or for cease of collection, process, use and/or international transmission of the same. Nevertheless, CTBC may therefore be unable to provide you with the requested services. In addition, CTBC may decline to follow your aforementioned request pursuant to relevant laws or its risk management policy, etc.

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* ※本 次 股 東 常 💸 恕 不 發 放 紀 念 品 🖇

\* \* \* \* \* \* \* \* \* \* \* \* \* \*

tanvex

2025 Annual General Meeting Notice

100 - 003台北市中正區重慶南路一段83號5樓英屬開曼群島商泰福生技股份有限公司(股票代號:6541)股務代理人中國信託商業銀行代理部 客服專線:(02)6636-5566

100-003 5F, No. 83, Sec. 1, Chongqing S. Rd., Taipei, Taiwan R.O.C. Stock Affairs Agency of Tanvex BioPharma, Inc. (Stock code: 6541) Stock Affairs Agency Department of CTBC Bank Co., Ltd. TEL No.:+886-2-6636-5566

聯 (First

開會通知請速詳閱

己

(限向郵局窗口交寄)

台北郵局許可證 台北字第1333號

Shareholder



出席簽到卡 **Attendance Card** 

本股東決定親自出席本公司西元 2025年6月5日舉行之股東常會, 請察照。

Please be informed that I/We will attend the 2025 Annual General Meeting on June 5, 2025.

此 致

英屬開曼群島商泰福生技股份有限公司

To Tanvex BioPharma, Inc.

tration

No. of

股東户名 Name of

親自出席簽章處 Signature

英屬開曼群島商泰福生技股份有限公司西元2025年股東常會 2025 Annual General Meeting of Tanvex BioPharma, Inc.

時間:西元2025年6月5日上午9時整

Time: June 5, 2025, 9:00 a.m., Taipei Time

也點:台北市中正區中山南路11號10樓張榮發基金會國際會議中心 ocation: CHANG YUNG-FA FOUNDATION International Convention Center

10F, No.11, Zhongshan S. Rd., Zhongzheng Dist., Taipei City

股東戶號:

Shareholder No.

持有股數:

Share(s) held

728 泰福-KY Tanvex

- 一、委託書應依公開發行公司出席股東會使用委託書規則及本公司第十次修正之章程第62至72條規定辦理。
  - The use of proxies is authorized in accordance with the Regulations Governing the Use of Proxies for Attendance at Shareholder Meeting of Public Companies (the "Regulations") and Articles 62 to 72 of the Company's Tenth Amended Articles of Incorporation.
- 二、股東接受他人徵求委託書前,應請徵求人提供徵求委託書之書面及廣告內容資料,或參考公司彙總之徵求 人書面及廣告資料,切實瞭解徵求人與擬支持被選舉人之背景資料及徵求人對股東會各項議案之意見。

Please make a request for the provision of contents of proxy solicitation letters and printing materials, or reference solicitors' proxy statements and printing materials compiled by the Company before issuing your proxy in order to figure out the backgrounds of both the solicitor and the director candidate and the solicitors' opinions to the items of Meeting accurately.

三、股東應使用本公司印發之委託書用紙,委託書與親自出席均簽名或蓋章者,視爲親自出席;但委託書由股 東交付徵求人或受託代理人者視爲委託出席。

Please use the Proxy Statement printed by the Company. In case the Company receives both signed or sealed Proxy Statement and Notice of Attendance from a shareholder, such shareholder will be deemed attending the Meeting in person unless the Proxy Statement is delivered to the solicitor or the proxy

委託書應由委託人親自簽名或蓋章,並應由委託人親自填具徵求人或受託代理人姓名。但信託事業或股務 代理機構受委託擔任徵求人,及股務代理機構受委任擔任委託書之受託代理人者,得以當場蓋章方式代替

The shareholder shall fill out the name of the solicitor or the proxy agent in the Proxy Statement and sign or affix seals on the proxies in person; however, in the situation where a trust enterprise or stock affairs agency acts as the solicitor and a stock affairs agency mandated to act as the proxy agent, seals be affixed on the proxies in substitution shall be permitted.

五、徵求人或受託代理人應於委託書上簽名或蓋章,並詳填户號、姓名或名稱、身分證字號或統一編號、住址。 受託代理人如非股東,請於股東户號欄內填寫身分證字號或統一編號;徵求人如爲信託事業、股務代理機 構,請於股東户號欄內填寫統一編號。

Solicitor or proxy agent shall sign or seal in the Proxy Statement and fill out the number of the shareholder, name, identification number and address. The proxy agent who is not the shareholder of the Company shall fill the identification number or unified business number in the column of Shareholder Number; on the other hand, in the situation where a trust enterprise or stock affairs agent acts as the solicitor, the proxy agent shall fill its unified business number in the column of Shareholder Number.

委託書應於開會五日前送達本公司股務代理人中國信託商業銀行代理部;委託書送達公司後,股東欲親自 出席股東會或欲以書面或電子方式行使表決權者,應於股東會開會二日前,以書面向公司為撤銷委託之通 知;逾期撤銷者,以委託代理人出席行使之表決權爲準。

The Proxy Statement shall be deposited at the Company's Stock Affairs Agency Department of CTBC Bank Co., Ltd., at least five (5) days prior to the Meeting date. In the event that any shareholder who has appointed a proxy to attend a general meeting later intends to attend the meeting in person or to exercise his voting power by way of a written ballot or through electronic transmission, he shall, at least two (2) days prior to the date of such general meeting, serve the Company with a separate written notice revoking his previous appointment of the proxy. Votes by way of proxy shall remain valid if the relevant shareholder fails to revoke his appointment of such proxy before the prescribed time.

				_	
委 託	書	ı	委託人(股東)	編	<b>∞</b> 泰福-KY
Proxy Statement	_		(Proxy by shareholder)	就 No	728 菜 個 「
1. 蒸委託 君(領由委託人親自填寫,不得以蓋	#.L÷/700	_	silarenoider)	۲	
1. 無要託 若(須田安託入稅目項馬,不行以益章方式代替)爲本股東代理人,出席本公司西元2025年6月5日舉行之股東常會,	一、禁止交付現金或	股本			l
平方式代替)為本版來代理人,出佈本公司四元2025年6月5日奉行之版來希賈, 代理人並依下列授權行使股東權利:	其他利益之價購	東戸號		簽	l
	委託書行為。	號		名	l
I hereby appoint(please fill out) as my proxy agent, with authorization to vote and act on my behalf at the 2025 Annual General		Z O		簽名或蓋	l
Meeting of the Members of Tanvex BioPharma, Inc. on June 5, 2025 pursuant	Offering cash or	١٠			l
to authorization scope described below:	non-cash	姓		章	l
□(1)代理本股東就會議事項行使股東權利。(全權委託)	consideration in	名或			l
I grant my proxy full authorization to vote, act on my behalf at the	exchange for	名或名稱Name			l
Meeting and act for extemporary motions during the Meeting.		Na a			l
(Authorization granted in full scope)	proxies is	me		Sign	l
□(2)代理本股東就下列各項議案行使本股東所委託表示之權利與意見,下列	prohibited for	4.6-		g	l
議案未勾選者,視爲對各該議案表示承認或贊成。	Proxy solicitation.	持有股數 Shareholding		익	l
I grant my proxy authorization to vote and act on my behalf at the		搬车		Sea	l
Meeting pursuant to authorized methods of exercise described below:	二、發現違法取得及	Shan		<u>=</u>	l
(If neither box is ticked, it will be deemed as "vote-for".)	使用委託書,可	황			l
a, 2024年度營業報告書及合併財務報告案:	檢附具體事證向	®.			
2024 Business Report and Consolidated Financial Report.	集保結算所檢		微 求 人		簽名或蓋章
(1)○承認(2)○反對(3)○棄權			Solicitor		Sign or Seal
(1) For (2) Against(3) Abstain	舉,經查證屬實	_	Tollicitor	_	Oigil of Ocul
b.2024年度虧損撥補案:	者,最高給予檢				
2024 Deficit Compensation.	舉獎金二十萬元,	P			
(1)○承認(2)○反對(3)○棄權		號			
(1) For (2) Against(3) Abstain	檢舉電話:	l _ l			
c.修訂「公司章程」部分條文案(本案應以特別決議通過):	(○二)二五四七	NO.			
Proposal for Amendments to Certain Articles of the Company's "Articles	三七三三。	١.			
of Association".(To be approved by special resolution)				$\neg$	
(1)○贊成(2)○反對(3)○棄權	Please report to	姓			
(1)○For (2)○Against(3)○Abstain	Taiwan	姓名或名稱			
d.臨時動議。	Depository &	名 稱			
Special Motion	Clearing	Name			
2.本股東未於前項□內勾選授權範圍或同時勾選者,视爲全權委託,但股務代理	Corporation	ne			
機構擔任受託代理人者,不得接受全權委託,代理人應依前項(2)之授權內容					
行使股東權利。	("TDCC")		受託代理人		簽名或蓋章
If neither authorization scope box is checked in the former item, it will be	supplementing		Proxy Agent		Sign or Seal
deemed as "authorization granted in full scope". However, whenever a	with specific	$\vdash$	, , ,	$\longrightarrow$	•
stock affairs agency mandated to act as the proxy agent, no		P			
authorization granted in full scope shall be permitted. The proxy agent	information when	號			
shall vote and act on behalf the Member pursuant to authorization methods of exercise described as item 1.(2).	discovering any	Z <sub>0</sub>			
3.本股東代理人得對會議臨時事宜全權處理之。	suspicious illegal				
3. 本版来代理人特別音歌師時爭且宝作處理人。 The proxy agent may have the authorization to act on the Member's behalf	obtaining or use	姓名或名稱Name			
for extemporary motions during the Meeting.		或名			
4.請將出席證(或出席簽到卡)寄交代理人收執,如因故改期開會,本委託書仍	of proxies. Once	稱			
屬有效(限此一會期)。	verified by TDCC,	ame			
Please deliver the Attendance Card to proxy agent. This Proxy will remain	the person making	或身統分		$\dashv$	
effective at any adjournment or postponement of the Meeting.	the report will be	が が が が が が が が が が が が が が			
此致to		一 維 統 就			
	granted a reward	D No			
英屬開曼群島商泰福生技股份有限公司	up to NTD				
投權日期 年 月 日	200,000. Report	住			
		址 A			
Tanvex BioPharma, Inc.	phone number:	Addre			

授權日期	年	月	E
Tanvex Bi			-
徴求場所 Signature by the p	及人 lace of solid	員簽 citation and	章處:   personnel:
٦			